Clinical Trial: JSKN022 in Subjects With Advanced Malignant Solid Tumors

U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07292402) titled 'JSKN022 in Subjects With Advanced Malignant Solid Tumors' on Nov. 13.

Brief Summary: The goal of this clinical trial is to learn if drug JSKN022 is safe to treat patients with advanced malignant solid tumors. It will also learn about the pharmacokinetic/ pharmacodynamic profiles and preliminary antitumor activity of drug JSKN022.

Study Start Date: Oct. 23

Study Type: INTERVENTIONAL

Condition: Advanced Malignant Solid Tumors

Intervention: DRUG: JSKN022

JSKN022 administered intravenously at selected dose levels according to protocol

Recruitment Status: RECRUITING

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Disclaim...